Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act

Advocating for meaningful reform of the Toxic Substances Control Act, including making improvements to H.R.2576, the TSCA Modernization Act of 2015; S. 697, the Frank R. Lautenberg Chemical Safety for the 21st Century Act; and S.725, the Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act. Working for reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocating for meaningful reform of the Toxic Substances Control Act, including making improvements to H.R.2576, the TSCA Modernization Act of 2015; S. 697, the Frank R. Lautenberg Chemical Safety for the 21st Century Act; and S.725, the Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act. Working for reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation in the 114th Congress: S. 1014, Personal Care Products Safety Act The Breast Cancer Fund continues to meet with staff from Senator Feinsteins office and other HELP committee offices to encourage legislative action on the issue of safety of Personal Care Products. The Breast Cancer Fund supports action that would effectively regulate Personal Care Products and Cosmetics to protect the health of consumers, workers, and communities. The Breast Cancer Fund also continues to meet with staff from House offices to encourage introduction of legislation in the House to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts. S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. S. 821, BPA in Food Packaging Right to Know Act The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A, which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund supports action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers. S. 3412, Ban Poisonous Additives Act of 2016 The Breast Cancer Fund supports this legislation that would ban bisphenol-A in food containers and prevent manufacturers from replacing bisphenol-A in food containers with unsafe alternatives because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. H.R. 6269, Ban Poisonous Additives Act of 2016 The Breast Cancer Fund supports this legislation that would ban bisphenol-A in food containers and prevent manufacturers from replacing bisphenol-A in food containers with unsafe alternatives because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. H.R. 5205, Cleaning Product Right to Know Act of 2016 The Breast Cancer Fund supports this bill that would require cleaning products to be labeled with all the ingredients contained therein. The Breast Cancer Fund has been meeting with House offices to urge Members to cosponsor the bill, and also with Senate offices to urge Senators to take up the issue in the Senate. HOUSE AND SENATE APPROPRIATIONS The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) The Breast Cancer Fund contacted Senate offices about preserving the current Design for the Environment program in the EPA. FUTURE LEGISLATIVE PROPOSALS: The Breast Cancer Fund visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC). The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. The Breast Cancer Fund supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS). REGULATION AND LEGISLATIVE INTENT: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally. P.L. 110-314 - The Consumer Product Safety Commission Improvement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation. P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act The Breast Cancer Fund is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).

Client expense: Not reported · Firm income: $10,000

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE

Legislation and policies related to: H.R. 2576 - TSCA Modernization Act H.R. 4470 - Safe Drinking Water Act Improved Compliance Awareness Act S. 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act S. 725 - Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act

Client expense: Not reported · Firm income: $23,450

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office

H.R. 185, Regulatory Accountability Act of 2015; H.R. 527; Small Business Regulatory Flexibility Improvements Act of 2015; H.R. 1029, EPA Science Advisory Board Reform Act of 2015; H.R. 1030, Secret Science Reform Act of 2015; H.R. 1321, Microbead-Free Waters Act of 2015; H.R. 2576; TSCA Modernization Act of 2015; H.R. 2577, Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2016; H.R. 2822, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2016; H.R. 2995, Financial Services and General Government Appropriations Act, 2016; H.R. 3977, Trash Reduction Act of 2015; H.R. 4923, American Manufacturing Competitiveness Act of 2016; H.R. 5538, Department of the Interior, Environment, and Related Agencies Appropriations Act of 2017; S. 543, EPA Science Advisory Board Reform Act of 2015; S. 544, Secret Science Reform Act of 2015; S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act; S. 700, READ Act; S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act; S. 821, BPA in Food Packaging Right to Know Act; S. 1014, Personal Care Products Safety Act; S. 1447, Sustainable Chemistry Research and Development Act of 2015; S. 2794, American Manufacturing Competitiveness Act of 2016; S. 3068, Department of the Interior, Environment, and Related Agencies Appropriations Act of 2017; FY 2016 Appropriations of Department of Interior; FY 2016 Appropriations of Environmental Protection Agency; FY 2016 Appropriations Financial Services and General Government (Green Building Policies, Phthalates, CHAP and CPSC); FY 2016 Appropriations of Transportation, Housing and Urban Development, and Related Agencies; FY 2017 Appropriations of Commerce, Justice, Science and Related Agencies; FY 2017 Appropriations of Department of Interior; FY 2017 Appropriations of Financial Services and General Government; FY 2017 Appropriations of Department of Labor, Health and Human Services; A Bill to Provide for the Implementation of a Sustainable Chemistry Program, and for other Purposes; Alternative Fuel Tax Assessment; Bisphenol A; Building and Construction water infrastructure; Chemical Assessment; Chemical Safety Board; Chemistry Caucus (Creation and Recruitment); Chlorinated Paraffins; CPSC; CPSC Phthalates CHAP; Design for the Environment; Energy Recovery; Flame Retardants; Fluorotechnology; Formaldehyde; Good Science; Green Building Standards; Hexavalent Chromium; Integrated Risk Information System; Labeling, including GMOs; Microbeads; Microplastics; Nanotechnology; OSHA Letters of Interpretation (Chemical Concentrations, Process Safety, RAGAGEP); OSHA Crystalline Silica Rule; Permitting Reform; Phthalates; Promoting New Manufacturing Act; Rare Earths; Risk Assessment Improvements; Report on Carcinogens and International Agency for Research on Cancer; Science Advisory Board; SNUR; Styrene; T-TIP, MTB and Trade Promotion Authority; Titanium Dioxide; Toxic Substances Control Act (TSCA)(Including Confidential Business Information) and Lautenberg Chemical Safety Act Implementation (LCSA)

Client expense: $2,860,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Surface Transportation Board (STB), Transportation, Dept of (DOT), Treasury, Dept of

S.__/H.R.__ (Fairness in Nursing Home Arbitration Act); draft legislation not formally introduced as of 1-01-2017; relating to the use of arbitration agreements to resolve disputes involving nursing home cases and nursing home contracts. Lobbying with regard to CMS rulemaking on mandatory pre-dispute arbitration in nursing home residency contracts. Lobbying with regard to the Consumer Financial Protection Bureau rulemaking on forced arbitration. Lobbying with regard to the Education Department Rulemaking on forced arbitration. General lobbying with regard to the Federal Communications Commission and forced arbitration. S. 1122/H.R. 2079 (Court Legal Access and Student Support (CLASS) Act of 2015); makes procedures for the enforcement of arbitration agreements inapplicable to an enrollment agreement between a student and an institution of higher education (IHE). H.R. 2087/S. 1133 (Arbitration Fairness Act); prohibits mandatory, pre-dispute arbitration in consumer contracts. General lobbying with regard to the enforceability of mandatory, pre-dispute arbitration provisions in employment and consumer contracts, including financial consumer contracts and servicemember contracts for consumer products. General lobbying with regard to the ability of consumers and injured parties to bring class actions, including limitations on the ability to bring class actions involving the securities industry. S. 3491/H.R. 6423 (Justice for Victims of Fraud Act of 2016); amends the Truth in Lending Act and the Electronic Fund Transfer Act to prohibit pre-dispute arbitration agreements with consumers (i.e., agreements to arbitrate any future disputes between parties instead of pursuing the claims in court) from being valid or enforceable in disputes related to credit card accounts or personal bank accounts that are not subject to a final judgment by a court if the credit card or bank account was not issued in response to a request or application for that account. General lobbying with regard to the regulation of pre-dispute arbitration by the Federal Communications Commission. General lobbying on consumer protection provisions related to servicemember contracts for consumer products. S.__/H.R.__ (Civil Legal Access to Strong Safeguards); draft legislation not formally introduced as of 1-01-2017; amends the Class Action Fairness Act to ensure that consumers and injured parties in a class action are treated fairly and equally. General Lobbying with regard to the preemption of states causes of action involving medical device and drug manufacturers. General lobbying with regard to asbestos exposure and related health and environmental issues. S. 357/H.R. 526 (Furthering Asbestos Claim Transparency Act); amends Title 11 of the United States Code to require the public disclosure by trusts established under Section 524(g) of such Title, of quarterly reports that contain detailed information regarding the receipt and disposition of claims for injuries based on exposure to asbestos, and the filing of such reports with the Executive Office for United States Trustees. H.R. 1199 (Innocent Sellers Fairness Act); prevents undue disruption of interstate commerce by limiting civil actions brought against persons whose only role with regard to a product in the stream of commerce is as a lawful seller of the product. General lobbying with regard to alternative litigation funding. H.R. 54 (Frank Lautenberg Memorial Secure Chemical Facilities Act)/S. 697 (Frank R. Lautenberg Chemical Safety for the 21st Century Act)/S.725 (Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act); amends the Toxic Substances Control Act to reauthorize and modernize that Act, and for other purposes. H.R. 2576 (TSCA Modernization Act); provides for the safe and efficient flow of chemicals in interstate and foreign commerce; specific interest in provisions that would preempt state-based causes of action. Lobbying with regard to draft legislation related to PCB exposure and liability. General lobbying with regard to pesticide regulations. General lobbying with regard to the ongoing development of a proposed TAFT-TTIP trade agreement, specific interest in effect the trade agreement would have on state-based causes of action. General lobbying with regard to warranties of Energy Star-rated products and ability of consumers to bring a class action against manufacturers of Energy Star-rated products. H.R. 504/S. 1038 (Energy Star Program Integrity Act); clarifies that no express or implied warranty is provided by reason of a disclosure relating to voluntary participation in the Energy Star program. H.R. 2030/S. 700 (READ Act); amends the Asbestos Information Act of 1988 to establish a public database of asbestos-containing products, to require public disclosure of information pertaining to the manufacture, processing, distribution, and use of asbestos-containing products in the United States. Lobbying with regard to updating generic drug labeling rulemaking and responsibilities. H.R. 2841 (FAST Generics Act of 2015); amends the Federal Food, Drug, and Cosmetic Act to prohibit the license holder of a Food and Drug Administration (FDA)-approved drug or biological product from restricting availability of the medication for testing by a product developer seeking to develop a drug, generic drug, or biosimilar, including restricting availability with a risk evaluation and mitigation strategy (REMS). S. 3056 (Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016); provides for certain causes of action relating to delays of generic drugs and biosimilar biological products. Lobbying with regard to biosimilar naming and labeling. General lobbying with regard to off-label promotion of pharmaceutical products. H.R. 3304 (Foreign Manufacturers Legal Accountability Act of 2015); Requires foreign manufacturers of products imported into the US to establish registered agents in the United States who are authorized to accept service of process against such manufacturers. S. 2506 (Restoring Statutory Rights and Interests of the States Act of 2016); amends the Federal Arbitration Act to invalidate arbitration agreements between parties in certain commercial contracts or transactions if they require arbitration of a claim for damages or injunctive relief brought by an individual or small business arising from the alleged violation of a federal or state statute, the U.S. Constitution, or a state constitution, unless the written agreement to arbitrate is entered into by both parties after the claim has arisen and pertains solely to an existing claim. S. 1014 (Personal Care Products Safety Act); amends the Federal Food, Drug, and Cosmetic Act to require cosmetics companies to register their facilities with the Food and Drug Administration (FDA) and to submit to the FDA cosmetic ingredient statements that include the amounts of a cosmetic's ingredients. H.R. 4075 (Cosmetic Modernization Amendments of 2016); amends the Federal Food, Drug, and Cosmetic Act to establish new procedures and requirements for the registration of cosmetic manufacturing establishments, the submission of cosmetic and ingredient statements, and the reporting of serious cosmetic adverse events. H.R. 1195 (Bureau of Consumer Financial Protection Advisory Boards Act); amends the Consumer Financial Protection Act of 2010 to establish advisory boards. General lobbying regarding altering CFPB's operational structure and rulemaking authority. H.R. 1486 (Taking Account of Bureaucrats Spending Act of 2015 (TABS Act); amends the Consumer Financial Protection Act of 2010 to bring the Bureau of Consumer Financial Protection into the regular appropriations process. H.R. 5983 (Financial CHOICE Act of 2016); repealing provisions of the Dodd-Frank Act.

Client expense: $1,150,000 · Firm income: Not reported

Government targets: Consumer Financial Protection Bureau (CFPB), Education, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE

S.725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act and S.697, The Frank Lautenberg Chemical Safety for the 21st Century Act

Client expense: Not reported · Firm income: $160,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocating for meaningful reform of the Toxic Substances Control Act, including making improvements to H.R.2576, the TSCA Modernization Act of 2015; S. 697, the Frank R. Lautenberg Chemical Safety for the 21st Century Act; and S.725, the Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act. Working for reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Supporting the Cleaning Product Right to Know Act (H.R. 5205), which requires manufacturers of both consumer household and industrial cleaning products to disclose all intentionally-added ingredients on their product labels and websites.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocating for meaningful reform of the Toxic Substances Control Act, including making improvements to H.R.2576, the TSCA Modernization Act of 2015; S. 697, the Frank R. Lautenberg Chemical Safety for the 21st Century Act; and S.725, the Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act. Working for reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Supporting the Cleaning Product Right to Know Act (H.R. 5205), which requires manufacturers of both consumer household and industrial cleaning products to disclose all intentionally-added ingredients on their product labels and websites.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocating for meaningful reform of the Toxic Substances Control Act, including making improvements to H.R.2576, the TSCA Modernization Act of 2015; S. 697, the Frank R. Lautenberg Chemical Safety for the 21st Century Act; and S.725, the Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act. Working for reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Supporting the Cleaning Product Right to Know Act (H.R. 5205), which requires manufacturers of both consumer household and industrial cleaning products to disclose all intentionally-added ingredients on their product labels and websites.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 697, The Frank R. Lautenberg Chemical Safety for the 21st Century Act, advocate for reasonable chemicals use management. S. 725, The Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act, advocate for reasonable chemicals use management.

Client expense: $1,290,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Energy, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Telecommunications & Information Administration (NTIA), Office of Science & Technology Policy (OSTP), SENATE, Transportation, Dept of (DOT), U.S. Trade & Development Agency (USTDA), White House Office

S. 697, The Frank R. Lautenberg Chemical Safety for the 21st Century Act, advocate for reasonable chemicals use management. S. 725, The Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act, advocate for reasonable chemicals use management.

Client expense: $1,290,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Energy, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Telecommunications & Information Administration (NTIA), Office of Science & Technology Policy (OSTP), SENATE, Transportation, Dept of (DOT), U.S. Trade & Development Agency (USTDA), White House Office

Legislation in the 114th Congress: S. 1014, Personal Care Products Safety Act The Breast Cancer Fund continues to meet with staff from Senator Feinsteins office and other HELP committee offices to encourage legislative action on the issue of safety of Personal Care Products. The Breast Cancer Fund supports action that would effectively regulate Personal Care Products and Cosmetics to protect the health of consumers, workers, and communities. The Breast Cancer Fund also continues to meet with staff from House offices to encourage introduction of legislation in the House to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts. S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. S. 821, BPA in Food Packaging Right to Know Act The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A, which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund supports action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers. S. 3412, Ban Poisonous Additives Act of 2016 The Breast Cancer Fund supports this legislation that would ban bisphenol-A in food containers and prevent manufacturers from replacing bisphenol-A in food containers with unsafe alternatives because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. H.R. 6269, Ban Poisonous Additives Act of 2016 The Breast Cancer Fund supports this legislation that would ban bisphenol-A in food containers and prevent manufacturers from replacing bisphenol-A in food containers with unsafe alternatives because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. H.R. 5205, Cleaning Product Right to Know Act of 2016 The Breast Cancer Fund supports this bill that would require cleaning products to be labeled with all the ingredients contained therein. The Breast Cancer Fund has been meeting with House offices to urge Members to cosponsor the bill, and also with Senate offices to urge Senators to take up the issue in the Senate. HOUSE AND SENATE APPROPRIATIONS The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) The Breast Cancer Fund contacted Senate offices about preserving the current Design for the Environment program in the EPA. FUTURE LEGISLATIVE PROPOSALS: The Breast Cancer Fund visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC). The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. The Breast Cancer Fund supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS). REGULATION AND LEGISLATIVE INTENT: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally. P.L. 110-314 - The Consumer Product Safety Commission Improvement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation. P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act The Breast Cancer Fund is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).

Client expense: Not reported · Firm income: $10,000

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE

H.R. 185, Regulatory Accountability Act of 2015; H.R. 527; Small Business Regulatory Flexibility Improvements Act of 2015; H.R. 1029, EPA Science Advisory Board Reform Act of 2015; H.R. 1030, Secret Science Reform Act of 2015; H.R. 1321, Microbead-Free Waters Act of 2015; H.R. 2576; TSCA Modernization Act of 2015; H.R. 2577, Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2016; H.R. 2822, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2016; H.R. 2995, Financial Services and General Government Appropriations Act, 2016; H.R. 3977, Trash Reduction Act of 2015; H.R. 4923, American Manufacturing Competitiveness Act of 2016; H.R. 5538, Department of the Interior, Environment, and Related Agencies Appropriations Act of 2017; S. 543, EPA Science Advisory Board Reform Act of 2015; S. 544, Secret Science Reform Act of 2015; S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act; S. 700, READ Act; S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act; S. 821, BPA in Food Packaging Right to Know Act; S. 1014, Personal Care Products Safety Act; S. 1447, Sustainable Chemistry Research and Development Act of 2015; S. 2794, American Manufacturing Competitiveness Act of 2016; S. 3068, Department of the Interior, Environment, and Related Agencies Appropriations Act of 2017; FY 2016 Appropriations of Department of Interior; FY 2016 Appropriations of Environmental Protection Agency; FY 2016 Appropriations Financial Services and General Government (Green Building Policies, Phthalates, CHAP and CPSC); FY 2016 Appropriations of Transportation, Housing and Urban Development, and Related Agencies; Good Science; FY 2017 Appropriations of Commerce, Justice, Science and Related Agencies; FY 2017 Appropriations of Department of Interior; FY 2017 Appropriations of Financial Services and General Government; FY 2017 Appropriations of Department of Labor, Health and Human Services; A Bill to Provide for the Implementation of a Sustainable Chemistry Program, and for other Purposes; Alternative Fuel Tax Assessment; Bisphenol A; Building and Construction water infrastructure; Chemical Assessment; Chemical Safety Board; Chemistry Caucus (Creation and Recruitment); Chlorinated Paraffins; CPSC; CPSC Phthalates CHAP; Design for the Environment; Energy Recovery; Flame Retardants; Fluorotechnology; Formaldehyde; Green Building Standards; Hexavalent Chromium; Integrated Risk Information System; Labeling, including GMOs; Microbeads; Microplastics; Nanotechnology; OSHA Letters of Interpretation (Chemical Concentrations, Process Safety, RAGAGEP); OSHA Crystalline Silica Rule; Permitting Reform; Phthalates; Promoting New Manufacturing Act; Rare Earths; Risk Assessment Improvements; Report on Carcinogens; Science Advisory Board; SNUR; Styrene; T-TIP, MTB and Trade Promotion Authority; Titanium Dioxide; Toxic Substances Control Act (TSCA)(Including Confidential Business Information)

Client expense: $2,190,000 · Firm income: Not reported

Government targets: Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Surface Transportation Board (STB), Transportation, Dept of (DOT), Treasury, Dept of

Legislation and policies related to: H.R. 2576 - TSCA Modernization Act H.R. 4470 - Safe Drinking Water Act Improved Compliance Awareness Act S. 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act S. 725 - Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act

Client expense: Not reported · Firm income: $23,450

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office

S.__/H.R.__ (Fairness in Nursing Home Arbitration Act); draft legislation not formally introduced as of 10-01-2016; relating to the use of arbitration agreements to resolve disputes involving nursing home cases and nursing home contracts. Lobbying with regard to CMS rulemaking on mandatory pre-dispute arbitration in nursing home residency contracts. Lobbying with regard to the Consumer Financial Protection Bureau rulemaking on forced arbitration. Lobbying with regard to the Education Department Rulemaking on forced arbitration. General lobbying with regard to the Federal Communications Commission and forced arbitration. S. 1122/H.R. 2079 (Court Legal Access and Student Support (CLASS) Act of 2015); makes procedures for the enforcement of arbitration agreements inapplicable to an enrollment agreement between a student and an institution of higher education (IHE). H.R. 2087/S. 1133 (Arbitration Fairness Act); prohibits mandatory, pre-dispute arbitration in consumer contracts. General lobbying with regard to the enforceability of mandatory, pre-dispute arbitration provisions in employment and consumer contracts, including financial consumer contracts and servicemember contracts for consumer products. General lobbying with regard to the ability of consumers and injured parties to bring class actions, including limitations on the ability to bring class actions involving the securities industry. General lobbying on consumer protection provisions related to servicemember contracts for consumer products. S.__/H.R.__ (Civil Legal Access to Strong Safeguards); draft legislation not formally introduced as of 10-01-2016; amends the Class Action Fairness Act to ensure that consumers and injured parties in a class action are treated fairly and equally. General Lobbying with regard to the preemption of states causes of action involving medical device and drug manufacturers. General lobbying with regard to asbestos exposure and related health and environmental issues. S. 357/H.R. 526 (Furthering Asbestos Claim Transparency Act); amends Title 11 of the United States Code to require the public disclosure by trusts established under Section 524(g) of such Title, of quarterly reports that contain detailed information regarding the receipt and disposition of claims for injuries based on exposure to asbestos, and the filing of such reports with the Executive Office for United States Trustees. H.R. 1199 (Innocent Sellers Fairness Act); prevents undue disruption of interstate commerce by limiting civil actions brought against persons whose only role with regard to a product in the stream of commerce is as a lawful seller of the product. General lobbying with regard to alternative litigation funding. H.R. 54 (Frank Lautenberg Memorial Secure Chemical Facilities Act)/S. 697 (Frank R. Lautenberg Chemical Safety for the 21st Century Act)/S.725 (Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act); amends the Toxic Substances Control Act to reauthorize and modernize that Act, and for other purposes. H.R. 2576 (TSCA Modernization Act); provides for the safe and efficient flow of chemicals in interstate and foreign commerce; specific interest in provisions that would preempt state-based causes of action. Lobbying with regard to draft legislation related to PCB exposure and liability. General lobbying with regard to pesticide regulations. General lobbying with regard to the ongoing development of a proposed TAFT-TTIP trade agreement, specific interest in effect the trade agreement would have on state-based causes of action. General lobbying with regard to warranties of Energy Star-rated products and ability of consumers to bring a class action against manufacturers of Energy Star-rated products. H.R. 504/S. 1038 (Energy Star Program Integrity Act); clarifies that no express or implied warranty is provided by reason of a disclosure relating to voluntary participation in the Energy Star program. H.R. 2030/S. 700 (READ Act); amends the Asbestos Information Act of 1988 to establish a public database of asbestos-containing products, to require public disclosure of information pertaining to the manufacture, processing, distribution, and use of asbestos-containing products in the United States. Lobbying with regard to updating generic drug labeling rulemaking and responsibilities. H.R. 2841 (FAST Generics Act of 2015); amends the Federal Food, Drug, and Cosmetic Act to prohibit the license holder of a Food and Drug Administration (FDA)-approved drug or biological product from restricting availability of the medication for testing by a product developer seeking to develop a drug, generic drug, or biosimilar, including restricting availability with a risk evaluation and mitigation strategy (REMS). S. 3056 (Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016); provides for certain causes of action relating to delays of generic drugs and biosimilar biological products. Lobbying with regard to biosimilar naming and labeling. H.R. 3304 (Foreign Manufacturers Legal Accountability Act of 2015); Requires foreign manufacturers of products imported into the US to establish registered agents in the United States who are authorized to accept service of process against such manufacturers. S. 2506 (Restoring Statutory Rights and Interests of the States Act of 2016); amends the Federal Arbitration Act to invalidate arbitration agreements between parties in certain commercial contracts or transactions if they require arbitration of a claim for damages or injunctive relief brought by an individual or small business arising from the alleged violation of a federal or state statute, the U.S. Constitution, or a state constitution, unless the written agreement to arbitrate is entered into by both parties after the claim has arisen and pertains solely to an existing claim. S. 1014 (Personal Care Products Safety Act); amends the Federal Food, Drug, and Cosmetic Act to require cosmetics companies to register their facilities with the Food and Drug Administration (FDA) and to submit to the FDA cosmetic ingredient statements that include the amounts of a cosmetic's ingredients. H.R. 4075 (Cosmetic Modernization Amendments of 2016); amends the Federal Food, Drug, and Cosmetic Act to establish new procedures and requirements for the registration of cosmetic manufacturing establishments, the submission of cosmetic and ingredient statements, and the reporting of serious cosmetic adverse events. H.R. 1195 (Bureau of Consumer Financial Protection Advisory Boards Act); amends the Consumer Financial Protection Act of 2010 to establish advisory boards. General lobbying regarding altering CFPB's operational structure and rulemaking authority. H.R. 1486 (Taking Account of Bureaucrats Spending Act of 2015 (TABS Act); amends the Consumer Financial Protection Act of 2010 to bring the Bureau of Consumer Financial Protection into the regular appropriations process. H.R. 5983 (Financial CHOICE Act of 2016); repealing provisions of the Dodd-Frank Act.

Client expense: $1,750,000 · Firm income: Not reported

Government targets: Education, Dept of, Executive Office of the President (EOP), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE

Issues affecting production of polypropelyne and other plastics S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act H.R.2576 - TSCA Modernization Act of 2015

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act and S.697, The Frank Lautenberg Chemical Safety for the 21st Century Act

Client expense: Not reported · Firm income: $160,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Work on H.R.2576, The TSCA Modernization Act of 2015, S.725, the Toxic Chemical Protection Act, and S.697, the Lautenberg Chemical Safety Act, which amends the Toxic Substances Control Act, to address the preemptive effect of such legislation and to strengthen the current standard setting process under TSCA.

Client expense: Not reported · Firm income: $50,000

Government targets: Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT)

LEGISLATION IN THE 114TH CONGRESS​ S.1014, Personal Care Products Safety Act The Breast Cancer Fund continues to meet with staff from Senator Feinsteins office and other HELP committee offices to encourage legislative action on the issue of safety of Personal Care Products. The Breast Cancer Fund supports action that would remove toxins and regulate Personal Care Products and Cosmetics. H.R.2576, TSCA Modernization Act of 2015 The Breast Cancer Fund supports this bill and has been meeting with House and Senate offices to persuade members to take up the bill in the Senate. S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act The Breast Cancer Fund opposes this legislation without amendments, as it would do little to strengthen the current TSCA law, but continues to work with members of the Senate Committee on Environment and Public Works to improve and strengthen the bill. S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. S. 821, BPA in Food Packaging Right to Know Act The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A, which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund support action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers. HOUSE AND SENATE APPROPRIATIONS The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) The Breast Cancer Fund contacted Senate offices about preserving the current Design for the Environment program in the EPA. FUTURE LEGISLATIVE PROPOSALS: The Breast Cancer Fund visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC). The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic and personal care product ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. The Breast Cancer Fund continues to talk with staff from Senate offices about the introduction of legislation in the Senate to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts. REGULATION AND LEGISLATIVE INTENT: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally. P.L. 110-314 - The Consumer Product Safety Commission Improvement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation. Lobbying: U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Consumer Product Safety Commission (CPSC), National Institutes of Health (NIH), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Office of Management & Budget (OMB), Health & Human Services - Department of (HHS), Office of Science & Technology Policy (OSTP), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)

Client expense: Not reported · Firm income: $10,000

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE

Legislation and policies related to: H.R. 2576 - TSCA Modernization Act H.R. 4470 - Safe Drinking Water Act Improved Compliance Awareness Act S. 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act S. 725 - Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act

Client expense: Not reported · Firm income: $23,450

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office

H.R. 185, Regulatory Accountability Act of 2015; H.R. 527; Small Business Regulatory Flexibility Improvements Act of 2015; H.R. 1029, EPA Science Advisory Board Reform Act of 2015; H.R. 1030, Secret Science Reform Act of 2015; H.R. 1321, Microbead-Free Waters Act of 2015; H.R. 2576; TSCA Modernization Act of 2015; H.R. 2577, Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2016; H.R. 2822, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2016; H.R. 2995, Financial Services and General Government Appropriations Act, 2016; H.R. 3977, Trash Reduction Act of 2015; H.R. 4923, American Manufacturing Competitiveness Act of 2016; H.R. 5538, Department of the Interior, Environment, and Related Agencies Appropriations Act of 2017; S. 543, EPA Science Advisory Board Reform Act of 2015; S. 544, Secret Science Reform Act of 2015; S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act; S. 700, READ Act; S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act; S. 821, BPA in Food Packaging Right to Know Act; S. 1014, Personal Care Products Safety Act; S. 1447, Sustainable Chemistry Research and Development Act of 2015; S. 2794, American Manufacturing Competitiveness Act of 2016; S. 3068, Department of the Interior, Environment, and Related Agencies Appropriations Act of 2017; FY 2016 Appropriations of Department of Interior; FY 2016 Appropriations of Environmental Protection Agency; FY 2016 Appropriations Financial Services and General Government (Green Building Policies, Phthalates, CHAP and CPSC); FY 2016 Appropriations of Transportation, Housing and Urban Development, and Related Agencies; Good Science; FY 2017 Appropriations of Commerce, Justice, Science and Related Agencies; FY 2017 Appropriations of Department of Interior; FY 2017 Appropriations of Financial Services and General Government; FY 2017 Appropriations of Department of Labor, Health and Human Services; A Bill to Provide for the Implementation of a Sustainable Chemistry Program, and for other Purposes; Alternative Fuel Tax Assessment; Bisphenol A; Building and Construction water infrastructure; Chemical Assessment; Chemical Safety Board; Chemistry Caucus (Creation and Recruitment); Chlorinated Paraffins; CPSC; CPSC Phthalates CHAP; Design for the Environment; Energy Recovery; Flame Retardants; Fluorotechnology; Formaldehyde; Green Building Standards; Hexavalent Chromium; Integrated Risk Information System; Microbeads; Microplastics; Nanotechnology; OSHA Letters of Interpretation (Chemical Concentrations, Process Safety, RAGAGEP); OSHA Crystalline Silica Rule; Permitting Reform; Phthalates; Promoting New Manufacturing Act; Rare Earths; Risk Assessment Improvements; Report on Carcinogens; Science Advisory Board; SNUR; Styrene; T-TIP, MTB and Trade Promotion Authority; Toxic Substances Control Act (TSCA)(Including Confidential Business Information)

Client expense: $2,750,000 · Firm income: Not reported

Government targets: Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Surface Transportation Board (STB), Transportation, Dept of (DOT), Treasury, Dept of

Ongoing engagement regarding the fuel economy rule and the mid-term review; tailpipe emissions proposed Tier 3 rule; Toxic Substances Control Act Reform (S.697), (S.725); American Mineral Security Act of 2015 (S.883); Gas Tax Replacement Act of 2015 (H.R. 309). TSCA Modernization Act of 2015 (H.R. 2576). Sustainability.

Client expense: $1,860,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Natl Highway Traffic Safety Administration (NHTSA), SENATE, Securities & Exchange Commission (SEC), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office

Trans-Pacific Partnership; AD/CVD duty collections & enforcement; customs compliance issues; textile and apparel trade issues; WTO Information Technology Agreement; Worker Safety in Bangladesh; Trans-Atlantic Trade and Investment Partnership; Environmental Goods Agreement, WTO Trade Facilitation Agreement; (S. 697) - Frank R. Lautenberg Chemical Safety for the 21st Century Act; (S. 725) - Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act; (H.R. 644) - Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); Defending Public Safety Employees Retirement Act (P.L. 114-26); Trade Preferences Extension Act of 2015 (P.L. 114-71); (H.R. 2576) - TSCA Modernization Act of 2015; GSP Travel Goods; trade capacity building. Uzbekistan cotton, Miscellaneous Tariff Bill (MTB); Trafficking in Persons Report; S.JRes 28; H.R. 4923 American Manufacturing Competitiveness Act (P.L. 114-159).

Client expense: $750,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Consumer Financial Protection Bureau (CFPB), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Maritime Commission, Federal Reserve System, Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), SENATE, Securities & Exchange Commission (SEC), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR), White House Office

S. 697, The Frank R. Lautenberg Chemical Safety for the 21st Century Act, advocate for reasonable chemicals use management. S. 725, The Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act, advocate for reasonable chemicals use management.

Client expense: $1,290,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Science & Technology Policy (OSTP), SENATE, Transportation, Dept of (DOT), White House Office

S. 697, The Frank R. Lautenberg Chemical Safety for the 21st Century Act, advocate for reasonable chemicals use management. S. 725, The Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act, advocate for reasonable chemicals use management.

Client expense: $1,290,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Science & Technology Policy (OSTP), SENATE, Transportation, Dept of (DOT), White House Office

S 697, S 725, HR 2576 (became Pub.L. 114-182, the Frank R. Lautenberg Chemical Safety for the 21st Century Act

Client expense: $15,681 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues affecting production of polypropelyne and other plastics S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act H.R.2576 - TSCA Modernization Act of 2015

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.697 and H.R. 2576 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, all sections; and S.725 - Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act, all sections.

Client expense: $228,834 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.__/H.R.__ (Fairness in Nursing Home Arbitration Act); draft legislation not formally introduced as of 07-01-2016; relating to the use of arbitration agreements to resolve disputes involving nursing home cases and nursing home contracts. Lobbying with regard to CMS rulemaking on mandatory pre-dispute arbitration in nursing home residency contracts. Lobbying with regard to the Consumer Financial Protection Bureau rulemaking on forced arbitration. Lobbying with regard to the Education Department Rulemaking on forced arbitration. General lobbying with regard to the Federal Communications Commission and forced arbitration. S. 1122/H.R. 2079 (Court Legal Access and Student Support (CLASS) Act of 2015); makes procedures for the enforcement of arbitration agreements inapplicable to an enrollment agreement between a student and an institution of higher education (IHE). H.R. 2087/S. 1133 (Arbitration Fairness Act); prohibits mandatory, pre-dispute arbitration in consumer contracts. General lobbying with regard to the enforceability of mandatory, pre-dispute arbitration provisions in employment and consumer contracts, including financial consumer contracts and servicemember contracts for consumer products. General lobbying with regard to the ability of consumers and injured parties to bring class actions, including limitations on the ability to bring class actions involving the securities industry. General lobbying on consumer protection provisions related to servicemember contracts for consumer products. S.__/H.R.__ (Civil Legal Access to Strong Safeguards); draft legislation not formally introduced as of 07-01-2016; amends the Class Action Fairness Act to ensure that consumers and injured parties in a class action are treated fairly and equally. General Lobbying with regard to the preemption of states causes of action involving medical device and drug manufacturers. General lobbying with regard to asbestos exposure and related health and environmental issues. S. 357/H.R. 526 (Furthering Asbestos Claim Transparency Act); amends Title 11 of the United States Code to require the public disclosure by trusts established under Section 524(g) of such Title, of quarterly reports that contain detailed information regarding the receipt and disposition of claims for injuries based on exposure to asbestos, and the filing of such reports with the Executive Office for United States Trustees. H.R. 1199 (Innocent Sellers Fairness Act); prevents undue disruption of interstate commerce by limiting civil actions brought against persons whose only role with regard to a product in the stream of commerce is as a lawful seller of the product. General lobbying with regard to alternative litigation funding. H.R. 54 (Frank Lautenberg Memorial Secure Chemical Facilities Act)/S. 697 (Frank R. Lautenberg Chemical Safety for the 21st Century Act)/S.725 (Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act); amends the Toxic Substances Control Act to reauthorize and modernize that Act, and for other purposes. H.R. 2576 (TSCA Modernization Act); provides for the safe and efficient flow of chemicals in interstate and foreign commerce; specific interest in provisions that would preempt state-based causes of action. General lobbying with regard to the ongoing development of a proposed TAFT-TTIP trade agreement, specific interest in effect the trade agreement would have on state-based causes of action. General lobbying with regard to warranties of Energy Star-rated products and ability of consumers to bring a class action against manufacturers of Energy Star-rated products. H.R. 504/S. 1038 (Energy Star Program Integrity Act); clarifies that no express or implied warranty is provided by reason of a disclosure relating to voluntary participation in the Energy Star program. H.R. 2030/S. 700 (READ Act); amends the Asbestos Information Act of 1988 to establish a public database of asbestos-containing products, to require public disclosure of information pertaining to the manufacture, processing, distribution, and use of asbestos-containing products in the United States. Lobbying with regard to updating generic drug labeling rulemaking and responsibilities. H.R. 2841 (FAST Generics Act of 2015); amends the Federal Food, Drug, and Cosmetic Act to prohibit the license holder of a Food and Drug Administration (FDA)-approved drug or biological product from restricting availability of the medication for testing by a product developer seeking to develop a drug, generic drug, or biosimilar, including restricting availability with a risk evaluation and mitigation strategy (REMS). S. 3056 (Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016); provides for certain causes of action relating to delays of generic drugs and biosimilar biological products. Lobbying with regard to biosimilar naming and labeling. H.R. 3304 (Foreign Manufacturers Legal Accountability Act of 2015); Requires foreign manufacturers of products imported into the US to establish registered agents in the United States who are authorized to accept service of process against such manufacturers. S. 2506 (Restoring Statutory Rights and Interests of the States Act of 2016); amends the Federal Arbitration Act to invalidate arbitration agreements between parties in certain commercial contracts or transactions if they require arbitration of a claim for damages or injunctive relief brought by an individual or small business arising from the alleged violation of a federal or state statute, the U.S. Constitution, or a state constitution, unless the written agreement to arbitrate is entered into by both parties after the claim has arisen and pertains solely to an existing claim. S. 1014 (Personal Care Products Safety Act); amends the Federal Food, Drug, and Cosmetic Act to require cosmetics companies to register their facilities with the Food and Drug Administration (FDA) and to submit to the FDA cosmetic ingredient statements that include the amounts of a cosmetic's ingredients. H.R. 4075 (Cosmetic Modernization Amendments of 2016); amends the Federal Food, Drug, and Cosmetic Act to establish new procedures and requirements for the registration of cosmetic manufacturing establishments, the submission of cosmetic and ingredient statements, and the reporting of serious cosmetic adverse events. H.R. 1195 (Bureau of Consumer Financial Protection Advisory Boards Act); amends the Consumer Financial Protection Act of 2010 to establish advisory boards. General lobbying regarding altering CFPB's operational structure and rulemaking authority. H.R. 1486 (Taking Account of Bureaucrats Spending Act of 2015 (TABS Act); amends the Consumer Financial Protection Act of 2010 to bring the Bureau of Consumer Financial Protection into the regular appropriations process.

Client expense: $1,500,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT), Vice President of the U.S.

H.R. 1732 Regulatory Integrity Protection Act S. 697 Frank R. Lautenberg Chemical Safety for the 21st Century Act S. 725 Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act S. 1140 Federal Water Quality Protection Act Congressional Review Act Resolution to disapprove the WOTUS rule S. 2848 Water Resources Development Act of 2016 H.R. 5303 Water Resources Development Act of 2016

Client expense: Not reported · Firm income: $100,000

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Mine Safety & Health Administration (MSHA), Occupational Safety & Health Administration (OSHA), SENATE, Transportation, Dept of (DOT), U.S. Geological Survey (USGS)

S.725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act and S.697, The Frank Lautenberg Chemical Safety for the 21st Century Act

Client expense: Not reported · Firm income: $160,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Work on H.R.2576, The TSCA Modernization Act of 2015, S.725, the Toxic Chemical Protection Act, and S.697, the Lautenberg Chemical Safety Act, which amends the Toxic Substances Control Act, to address the preemptive effect of such legislation and to strengthen the current standard setting process under TSCA.

Client expense: Not reported · Firm income: $50,000

Government targets: Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT)

S. 697 Frank Lautenberg Chemical Safety for the 21st Century Act S. 725 Toxic Chemical Protection Act 2015 H.R. 2576 TSCA Modernization Act of 2015

Client expense: Not reported · Firm income: $48,000

Government targets: Army, Dept of (Corps of Engineers), Environmental Protection Agency (EPA), Federal Railroad Administration, HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Surface Transportation Board (STB), Transportation, Dept of (DOT), Treasury, Dept of

LEGISLATION IN THE 114TH CONGRESS​ S.1014, Personal Care Products Safety Act The Breast Cancer Fund continues to meet with staff from Senator Feinsteins office and other HELP committee offices to encourage legislative action on the issue of safety of Personal Care Products. The Breast Cancer Fund supports action that would remove toxins and regulate Personal Care Products and Cosmetics. H.R.2576, TSCA Modernization Act of 2015 The Breast Cancer Fund supports this bill and has been meeting with House and Senate offices to persuade members to take up the bill in the Senate. S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act The Breast Cancer Fund opposes this legislation without amendments, as it would do little to strengthen the current TSCA law, but continues to work with members of the Senate Committee on Environment and Public Works to improve and strengthen the bill. S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. S. 821, BPA in Food Packaging Right to Know Act The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A, which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund support action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers. HOUSE AND SENATE APPROPRIATIONS The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) The Breast Cancer Fund contacted Senate offices about preserving the current Design for the Environment program in the EPA. FUTURE LEGISLATIVE PROPOSALS: The Breast Cancer Fund visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC). The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic and personal care product ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. The Breast Cancer Fund continues to talk with staff from Senate offices about the introduction of legislation in the Senate to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts. REGULATION AND LEGISLATIVE INTENT: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally. P.L. 110-314 - The Consumer Product Safety Commission Improvement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation. Lobbying: U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Consumer Product Safety Commission (CPSC), National Institutes of Health (NIH), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Office of Management & Budget (OMB), Health & Human Services - Department of (HHS), Office of Science & Technology Policy (OSTP), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)

Client expense: Not reported · Firm income: $10,000

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE

Legislation and policies related to: H.R. 2576 - TSCA Modernization Act H.R. 4470 - Safe Drinking Water Act Improved Compliance Awareness Act S. 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act S. 725 - Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act

Client expense: Not reported · Firm income: $23,450

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office

Ongoing engagement regarding the fuel economy rule and the mid-term review; tailpipe emissions proposed Tier 3 rule; Toxic Substances Control Act Reform (S.697), (S.725); American Mineral Security Act of 2015 (S.883); Gas Tax Replacement Act of 2015 (H.R. 309). TSCA Modernization Act of 2015 (H.R. 2576).

Client expense: $2,870,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Natl Highway Traffic Safety Administration (NHTSA), SENATE, Securities & Exchange Commission (SEC), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office

H.R. 185, Regulatory Accountability Act of 2015; H.R. 527; Small Business Regulatory Flexibility Improvements Act of 2015; H.R. 1029, EPA Science Advisory Board Reform Act of 2015; H.R. 1030, Secret Science Reform Act of 2015; H.R. 1321, Microbead-Free Waters Act of 2015; H.R. 2576; TSCA Modernization Act of 2015; H.R. 2577, Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2016; H.R. 2822, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2016; H.R. 2995, Financial Services and General Government Appropriations Act, 2016; H.R. 3977, Trash Reduction Act of 2015; S. 543, EPA Science Advisory Board Reform Act of 2015; S. 544, Secret Science Reform Act of 2015; S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act; S. 700, READ Act; S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act; S. 821, BPA in Food Packaging Right to Know Act; S. 1014, Personal Care Products Safety Act; S. 1447, Sustainable Chemistry Research and Development Act of 2015; FY 2016 Appropriations of Department of Interior; FY 2016 Appropriations of Environmental Protection Agency; FY 2016 Appropriations Financial Services and General Government (Green Building Policies, Phthalates, CHAP and CPSC); FY 2016 Appropriations of Transportation, Housing and Urban Development, and Related Agencies; Good Science; FY 2017 Appropriations of Commerce, Justice, Science and Related Agencies; FY 2017 Appropriations of Department of Interior; FY 2017 Appropriations of Financial Services and General Government; FY 2017 Appropriations of Department of Labor, Health and Human Services; A Bill to Provide for the Implementation of a Sustainable Chemistry Program, and for other Purposes; Alternative Fuel Tax Assessment; Bisphenol A; Chemical Assessment; Chemical Safety Board; Chemistry Caucus (Creation and Recruitment); Chlorinated Paraffins; CPSC; CPSC Phthalates CHAP; Design for the Environment; Energy Recovery; Flame Retardants; Fluorotechnology; Formaldehyde; Green Building Standards; Hexavalent Chromium; Integrated Risk Information System; Microbeads; Microplastics; Nanotechnology; OSHA Letters of Interpretation (Chemical Concentrations, Process Safety, RAGAGEP); OSHA Crystalline Silica Rule; Permitting Reform; Phthalates; Promoting New Manufacturing Act; Rare Earths; Risk Assessment Improvements; Report on Carcinogens; Science Advisory Board; SNUR; Styrene; T-TIP, MTB and Trade Promotion Authority; Toxic Substances Control Act (TSCA)(Including Confidential Business Information)

Client expense: $1,220,000 · Firm income: Not reported

Government targets: Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Surface Transportation Board (STB), Transportation, Dept of (DOT), Treasury, Dept of

S.__/H.R.__ (Fairness in Nursing Home Arbitration Act); draft legislation not formally introduced as of 04-01-2016; relating to the use of arbitration agreements to resolve disputes involving nursing home cases and nursing home contracts. Lobbying with regard to CMS rulemaking on mandatory pre-dispute arbitration in nursing home residency contracts. Lobbying with regard to the Education Department Rulemaking on forced arbitration. General lobbying with regard to the Federal Communications Commission and forced arbitration. S. 1122/H.R. 2079 (Court Legal Access and Student Support (CLASS) Act of 2015); makes procedures for the enforcement of arbitration agreements inapplicable to an enrollment agreement between a student and an institution of higher education (IHE). H.R. 2087/S. 1133 (Arbitration Fairness Act); prohibits mandatory, pre-dispute arbitration in consumer contracts. General lobbying with regard to the enforceability of mandatory, pre-dispute arbitration provisions in employment and consumer contracts, including financial consumer contracts and servicemember contracts for consumer products. General lobbying with regard to the ability of consumers and injured parties to bring class actions, including limitations on the ability to bring class actions involving the securities industry. General lobbying on consumer protection provisions related to servicemember contracts for consumer products. S.__/H.R.__ (Civil Legal Access to Strong Safeguards); draft legislation not formally introduced as of 04-01-2016; amends the Class Action Fairness Act to ensure that consumers and injured parties in a class action are treated fairly and equally. General Lobbying with regard to the preemption of states causes of action involving medical device and drug manufacturers. General lobbying with regard to asbestos exposure and related health and environmental issues. S. 357/H.R. 526 (Furthering Asbestos Claim Transparency Act); amends Title 11 of the United States Code to require the public disclosure by trusts established under Section 524(g) of such Title, of quarterly reports that contain detailed information regarding the receipt and disposition of claims for injuries based on exposure to asbestos, and the filing of such reports with the Executive Office for United States Trustees. H.R. 1199 (Innocent Sellers Fairness Act); prevents undue disruption of interstate commerce by limiting civil actions brought against persons whose only role with regard to a product in the stream of commerce is as a lawful seller of the product. General lobbying with regard to alternative litigation funding. H.R. 54 (Frank Lautenberg Memorial Secure Chemical Facilities Act)/S. 697 (Frank R. Lautenberg Chemical Safety for the 21st Century Act)/S.725 (Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act); amends the Toxic Substances Control Act to reauthorize and modernize that Act, and for other purposes. H.R. 2576 (TSCA Modernization Act); provides for the safe and efficient flow of chemicals in interstate and foreign commerce; specific interest in provisions that would preempt state-based causes of action. General lobbying with regard to the ongoing development of a proposed TAFT-TTIP trade agreement, specific interest in effect the trade agreement would have on state-based causes of action. General lobbying with regard to warranties of Energy Star-rated products and ability of consumers to bring a class action against manufacturers of Energy Star-rated products. H.R. 504/S. 1038 (Energy Star Program Integrity Act); clarifies that no express or implied warranty is provided by reason of a disclosure relating to voluntary participation in the Energy Star program. H.R. 2030/S. 700 (READ Act); amends the Asbestos Information Act of 1988 to establish a public database of asbestos-containing products, to require public disclosure of information pertaining to the manufacture, processing, distribution, and use of asbestos-containing products in the United States. Lobbying with regard to updating generic drug labeling rulemaking and responsibilities. H.R. 2841 (FAST Generics Act of 2015); amends the Federal Food, Drug, and Cosmetic Act to prohibit the license holder of a Food and Drug Administration (FDA)-approved drug or biological product from restricting availability of the medication for testing by a product developer seeking to develop a drug, generic drug, or biosimilar, including restricting availability with a risk evaluation and mitigation strategy (REMS). H.R. 3304 (Foreign Manufacturers Legal Accountability Act of 2015); Requires foreign manufacturers of products imported into the US to establish registered agents in the United States who are authorized to accept service of process against such manufacturers. S. 2506 (Restoring Statutory Rights and Interests of the States Act of 2016); amends the Federal Arbitration Act to invalidate arbitration agreements between parties in certain commercial contracts or transactions if they require arbitration of a claim for damages or injunctive relief brought by an individual or small business arising from the alleged violation of a federal or state statute, the U.S. Constitution, or a state constitution, unless the written agreement to arbitrate is entered into by both parties after the claim has arisen and pertains solely to an existing claim. S. 1014 (Personal Care Products Safety Act); amends the Federal Food, Drug, and Cosmetic Act to require cosmetics companies to register their facilities with the Food and Drug Administration (FDA) and to submit to the FDA cosmetic ingredient statements that include the amounts of a cosmetic's ingredients. H.R. 4075 (Cosmetic Modernization Amendments of 2016); amends the Federal Food, Drug, and Cosmetic Act to establish new procedures and requirements for the registration of cosmetic manufacturing establishments, the submission of cosmetic and ingredient statements, and the reporting of serious cosmetic adverse events. H.R. 1195 (Bureau of Consumer Financial Protection Advisory Boards Act); amends the Consumer Financial Protection Act of 2010 to establish advisory boards. General lobbying regarding altering CFPB's operational structure and rulemaking authority.

Client expense: $1,380,000 · Firm income: Not reported

Government targets: Consumer Financial Protection Bureau (CFPB), Education, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, Vice President of the U.S.

S. 697, The Frank R. Lautenberg Chemical Safety for the 21st Century Act, advocate for reasonable chemicals use management. S. 725, The Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act, advocate for reasonable chemicals use management.

Client expense: $1,730,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Science & Technology Policy (OSTP), SENATE, Transportation, Dept of (DOT), White House Office

S. 697, The Frank R. Lautenberg Chemical Safety for the 21st Century Act, advocate for reasonable chemicals use management. S. 725, The Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act, advocate for reasonable chemicals use management.

Client expense: $1,730,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Science & Technology Policy (OSTP), SENATE, Transportation, Dept of (DOT), White House Office

S 544, HR 1030 Secret Science Reform Act S 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act, a bill to amend the Toxic Substances Control Act to reauthorize and modernize that Act S 725 Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act, A bill to amend the Toxic Substances Control Act HR 2576 TSCA Modernization Act of 2015 HR 185 Regulatory Accountability Act S 708 Regulatory Improvement Act of 2015

Client expense: $36,139 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act and S.697, The Frank Lautenberg Chemical Safety for the 21st Century Act

Client expense: Not reported · Firm income: $160,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.697, Frank R. Lautenberg Chemical Safety for the 21st Century Act; S.725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act; H.R.2576, TSCA Modernization Act of 2015; issues related to Toxic Substances Control Act (TSCA) reform.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE